CANY
VYGR icon

Caxton Associates (New York)’s Voyager Therapeutics VYGR Stock Holding History

Caxton Associates (New York)’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,005
Closed -$252K – 609
2023
Q2 		$252K Sell
22,005
-14,559
-40% -$151K 0.04% 377
2023
Q1 		$282K Sell
36,564
-70,132
-66% -$558K 0.04% 364
2022
Q4 		$651K Sell
106,696
-29,896
-22% -$170K 0.04% 192
2022
Q3 		$809K Hold
136,592
– – 0.11% 156
2022
Q2 		$807K Hold
136,592
– – 0.08% 167
2022
Q1 		$1.04M Buy
+136,592
New +$609K 0.08% 99

Other funds holding VYGR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Caxton Associates (New York)'s VYGR Position: Q3 2023 in Review

Caxton Associates (New York) sold out of Voyager Therapeutics (VYGR) in Q3 2023, closing a stake of 22,005 shares — an estimated $252K sold.

Caxton Associates (New York) first reported a position in VYGR in Q1 2022 and held it in 6 quarters. The position peaked at $1.04M in Q1 2022. 110 funds tracked by Wall St. Rank hold VYGR as of Q3 2023.

  • Caxton Associates (New York) reported no remaining Voyager Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 22,005 Voyager Therapeutics shares in Q3 2023, an estimated $252K.
  • Caxton Associates (New York) first reported a position in Voyager Therapeutics in Q1 2022 and held it in 6 quarters.
  • Caxton Associates (New York)'s Voyager Therapeutics position peaked at $1.04M in Q1 2022.
  • 110 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q3 2023.

Based on Caxton Associates (New York)'s 13F filing for Q3 2023, filed 14 Nov 2023.